{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:45:41Z","timestamp":1792521941617,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.autrev.2025.103900","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:11:22Z","timestamp":1754439082000},"page":"103900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases"],"prefix":"10.1016","volume":"24","author":[{"given":"Yasuhiro","family":"Kondoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0005","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12931-024-02751-z","article-title":"Response to: are there over 200 distinct types of interstitial lung diseases?","volume":"25","author":"Amati","year":"2024","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12931-024-02734-0","article-title":"Are there over 200 distinct types of interstitial lung diseases?","volume":"25","author":"Cooley","year":"2024","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.autrev.2025.103900_bb0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.autrev.2025.103900_bb0020","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease: a review","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir Investig"},{"issue":"8","key":"10.1016\/j.autrev.2025.103900_bb0030","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"167","key":"10.1016\/j.autrev.2025.103900_bb0035","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0210-2022","article-title":"Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis","volume":"32","author":"Joy","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.autrev.2025.103900_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684699","article-title":"Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations","volume":"12","author":"Shao","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.rdc.2024.03.001","article-title":"Connective tissue disease associated interstitial lung disease","volume":"50","author":"Matson","year":"2024","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"10.1016\/j.autrev.2025.103900_bb0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2025.103900_bb0055","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/art.42640","article-title":"Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease","volume":"75","author":"Koduri","year":"2023","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0060","article-title":"Management of myositis-associated interstitial lung disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.31138\/mjr.230323.cca","article-title":"Clinical characteristics and outcomes of interstitial lung disease in primary Sjogren\u2019s syndrome: a retrospective cohort study","volume":"35","author":"Manikuppam","year":"2024","journal-title":"Mediterr J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103900_bb0070","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0075","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"issue":"150","key":"10.1016\/j.autrev.2025.103900_bb0080","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.autrev.2025.103900_bb0085","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/03009741003604542","article-title":"Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA","volume":"39","author":"Nakajima","year":"2010","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0090","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103900_bb0095","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3899\/jrheum.101002","article-title":"Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan","volume":"38","author":"Yamasaki","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/14397595.2015.1054081","article-title":"Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors","volume":"26","author":"Ishizuka","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0105","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/BOR.0000000000000544","article-title":"Recent progress in systemic sclerosis-interstitial lung disease","volume":"30","author":"Castelino","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.berh.2016.03.002","article-title":"Mixed connective tissue disease","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0120","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.autrev.2025.103900_bb0125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/resp.14245","article-title":"Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype","volume":"27","author":"Takei","year":"2022","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0130","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.resinv.2024.05.005","article-title":"Progressive pulmonary fibrosis (PPF): estimation of incidence and treatment rates in Japan using a claims database","volume":"62","author":"Kondoh","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.autrev.2025.103900_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107242","article-title":"Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease","volume":"212","author":"Lee","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2025.103900_bb0140","article-title":"Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: a cohort study","volume":"10","author":"Chiu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2025.103900_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106579","article-title":"Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases","volume":"187","author":"Chiu","year":"2021","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1164\/rccm.202201-0124OC","article-title":"Validation of proposed criteria for progressive pulmonary fibrosis","volume":"207","author":"Pugashetti","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032405","article-title":"Understanding interstitial lung diseases associated with connective tissue disease (CTD-ILD): genetics, cellular pathophysiology, and biologic drivers","volume":"24","author":"Cerro Chiang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/ar3097","article-title":"Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management","volume":"12","author":"Castelino","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0165","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00481-2021","article-title":"Autoantibodies are present in the bronchoalveolar lavage but not circulation in patients with fibrotic interstitial lung disease","volume":"8","author":"Boustani","year":"2022","journal-title":"ERJ Open Res"},{"issue":"18","key":"10.1016\/j.autrev.2025.103900_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814385","article-title":"Endothelial dysfunction in systemic sclerosis","volume":"24","author":"Patnaik","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070847","article-title":"Endothelial progenitor cells: relevant players in the vasculopathy and lung fibrosis associated with the presence of interstitial lung disease in systemic sclerosis patients","volume":"9","author":"Pulito-Cueto","year":"2021","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.autrev.2025.103900_bb0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11926-016-0618-4","article-title":"The complex role of the lung in the pathogenesis and clinical outcomes of rheumatoid arthritis","volume":"18","author":"Kelmenson","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17476348.2023.2176303","article-title":"Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements","volume":"17","author":"Kuwana","year":"2023","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0190","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/mr\/roae033","article-title":"Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension using a Japanese claims database","volume":"34","author":"Tokushige","year":"2024","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103900_bb0195","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0200","doi-asserted-by":"crossref","first-page":"e1442","DOI":"10.1210\/clinem\/dgad701","article-title":"Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis","volume":"109","author":"Koning","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.autrev.2025.103900_bb0205","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0210","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.resinv.2024.11.003","article-title":"Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil","volume":"62","author":"Takada","year":"2024","journal-title":"Respir Investig"},{"issue":"25","key":"10.1016\/j.autrev.2025.103900_bb0215","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2025.103900_bb0220","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103900_bb0225","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1159\/000509612","article-title":"Azathioprine for connective tissue disease-associated interstitial lung disease: in search for evidence-based medicine","volume":"99","author":"Tzilas","year":"2020","journal-title":"Respiration"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0230","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00296-023-05336-z","article-title":"Management of myositis associated interstitial lung disease","volume":"43","author":"Thong","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103900_bb0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin a","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review","volume":"20","author":"Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2025.103900_bb0250","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.autrev.2025.103900_bb0255","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.autrev.2025.103900_bb0260","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.autrev.2025.103900_bb0265","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.autrev.2025.103900_bb0270","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.resinv.2020.03.005","article-title":"A new therapy for systemic sclerosis-associated interstitial lung disease","volume":"58","author":"Kondoh","year":"2020","journal-title":"Respir Investig"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0280","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12890-024-03314-0","article-title":"Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease","volume":"24","author":"Aggarwal","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0285","article-title":"Efficacy and safety of nintedanib in patients with connective tissue disease-interstitial lung disease (CTD-ILD): a real-world single center experience","volume":"13","author":"Boutel","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0290","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10067-025-07323-0","article-title":"Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: a multicenter retrospective study","volume":"44","author":"Misirci","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103900_bb0295","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1007\/s12325-024-03023-4","article-title":"Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: post-marketing data","volume":"41","author":"Chaudhuri","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0300","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00529-2023","article-title":"Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK","volume":"10","author":"Dixon","year":"2024","journal-title":"ERJ Open Res"},{"issue":"10","key":"10.1016\/j.autrev.2025.103900_bb0305","first-page":"753","article-title":"Safety and tolerability of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: first interim report of a 2\u2013year post\u2013marketing surveillance","volume":"44","author":"Ito","year":"2023","journal-title":"Ther Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0310","first-page":"27","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis\u2013associated interstitial lung disease in clinical practice: interim analysis of post\u2013marketing surveillance in Japan","volume":"45","author":"Saito","year":"2024","journal-title":"Ther Res"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1335","article-title":"Pirfenidone use in fibrotic diseases: what do we know so far?","volume":"12","author":"Torre","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"5","key":"10.1016\/j.autrev.2025.103900_bb0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.autrev.2025.103900_bb0325","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"22","key":"10.1016\/j.autrev.2025.103900_bb0335","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"9779","key":"10.1016\/j.autrev.2025.103900_bb0340","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0345","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.autrev.2025.103900_bb0350","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/thorax-2022-219391","article-title":"Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial","volume":"78","author":"West","year":"2023","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.autrev.2025.103900_bb0355","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/14712598.5.5.683","article-title":"The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody","volume":"5","author":"Mihara","year":"2005","journal-title":"Expert Opin Biol Ther"},{"issue":"10038","key":"10.1016\/j.autrev.2025.103900_bb0360","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.autrev.2025.103900_bb0365","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2005.03.013","article-title":"Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis","volume":"39","author":"Hasegawa","year":"2005","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0375","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1346-8138.2009.00763.x","article-title":"B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis","volume":"37","author":"Hasegawa","year":"2010","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0380","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/mr\/road040","article-title":"Role of rituximab in the treatment of systemic sclerosis: a literature review","volume":"33","author":"Yoshifuji","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0385","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0390","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31138\/mjr.33.1.1","article-title":"B cell depletion treatment in resistant systemic sclerosis interstitial lung disease","volume":"33","author":"Bounia","year":"2022","journal-title":"Mediterr J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0400","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41927-024-00374-x","article-title":"Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study","volume":"8","author":"Tsujii","year":"2024","journal-title":"BMC Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0405","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"10","key":"10.1016\/j.autrev.2025.103900_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103636","article-title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"23","author":"Narvaez","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0415","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2025.103900_bb0420","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf006","article-title":"Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis","author":"Goldman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2025.103900_bb0425","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00296-024-05695-1","article-title":"Tocilizumab plus nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study","volume":"44","author":"Panopoulos","year":"2024","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.autrev.2025.103900_bb0430","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103900_bb0435","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"Denton","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0440","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0445","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001563","article-title":"Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)","volume":"10","author":"Richeldi","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0455","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001580","article-title":"Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)","volume":"10","author":"Maher","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0460","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","article-title":"Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)","volume":"22","author":"Nasser","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2025.103900_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103900_bb0470","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0475","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ Res"},{"issue":"167","key":"10.1016\/j.autrev.2025.103900_bb0480","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.autrev.2025.103900_bb0485","author":"Human Proteome Atlas"},{"key":"10.1016\/j.autrev.2025.103900_bb0490","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103900_bb0495","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","volume":"9","author":"Chong","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0500","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1440-1843.2009.01606.x","article-title":"Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats","volume":"14","author":"Pan","year":"2009","journal-title":"Respirology"},{"issue":"12","key":"10.1016\/j.autrev.2025.103900_bb0505","article-title":"Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury","volume":"6","author":"Sisson","year":"2018","journal-title":"Phys Rep"},{"issue":"3","key":"10.1016\/j.autrev.2025.103900_bb0510","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1476-5381.2008.00041.x","article-title":"Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury","volume":"156","author":"Cortijo","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0515","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12890-022-01876-5","article-title":"Correction to: effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice","volume":"22","author":"Udalov","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0520","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0525","first-page":"119","article-title":"Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases","volume":"43","author":"Castelino","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103900_bb0530","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241309795","article-title":"Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis","volume":"19","author":"Keith","year":"2025","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0535","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004704","article-title":"Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases","volume":"10","author":"Aringer","year":"2024","journal-title":"RMD Open"},{"issue":"23","key":"10.1016\/j.autrev.2025.103900_bb0540","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1111\/bph.17303","article-title":"PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells","volume":"181","author":"Reininger","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2025.103900_bb0545","doi-asserted-by":"crossref","DOI":"10.1165\/rcmb.2024-0614OC","article-title":"Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast","author":"Reininger","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"23","key":"10.1016\/j.autrev.2025.103900_bb0550","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.autrev.2025.103900_bb0555","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.autrev.2025.103900_bb0560","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103900_bb0565","article-title":"Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease","author":"Khanna","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"issue":"21","key":"10.1016\/j.autrev.2025.103900_bb0570","doi-asserted-by":"crossref","first-page":"15549","DOI":"10.1021\/acs.jmedchem.1c01256","article-title":"Discovery of an oxycyclohexyl acid lysophosphatidic acid receptor 1 (LPA(1)) antagonist BMS-986278 for the treatment of pulmonary fibrotic diseases","volume":"64","author":"Cheng","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2025.103900_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108421","article-title":"Lysophosphatidic acid, a simple phospholipid with myriad functions","volume":"246","author":"Yanagida","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"172","key":"10.1016\/j.autrev.2025.103900_bb0580","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0015-2024","article-title":"Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis","volume":"33","author":"Volkmann","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.autrev.2025.103900_bb0585","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and safety of admilparant, an LPA(1) antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial","volume":"211","author":"Corte","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2025.103900_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2025.04.003","article-title":"Effect of admilparant, an LPA1 antagonist, on disease progression in pulmonary fibrosis","author":"Kreuter","year":"2025","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0595","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/fca-2020-0021","article-title":"Treprostinil in the treatment of pulmonary arterial hypertension","volume":"16","author":"Feldman","year":"2020","journal-title":"Futur Cardiol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0600","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103900_bb0605","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.autrev.2025.103900_bb0610","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s12325-022-02229-8","article-title":"The antifibrotic effects of inhaled treprostinil: an emerging option for ILD","volume":"39","author":"Kolb","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2025.103900_bb0615","article-title":"Study design and rationale for the TETON-PPF clinical trial of inhaled treprostinil for the treatment of progressive pulmonary fibrosis","volume":"209","author":"Nathan","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0620","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.autrev.2025.103900_bb0625","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1136\/annrheumdis-2023-eular.1990","article-title":"Belimumab for the treatment of interstitial lung disease associated with systemic sclerosis: a phase 2\/3 randomised, double-blind, placebo-controlled trial","volume":"82","author":"Denton","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2025.103900_bb0630","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/14728222.2024.2375375","article-title":"Potential of alphavbeta6 and alphavbeta1 integrin inhibition for treatment of idiopathic pulmonary fibrosis","volume":"28","author":"Bellani","year":"2024","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0635","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2025.103900_bb0640","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202410-1934OC","article-title":"Dual alphavbeta6 and alphavbeta1 inhibition over 12 weeks reduces active type 1 collagen deposition in individuals with idiopathic pulmonary fibrosis: a phase 2, double-blind, placebo-controlled clinical trial","author":"Montesi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0650","first-page":"36","article-title":"China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy","volume":"39","author":"Zhou","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.autrev.2025.103900_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2025.02.007","article-title":"Targeting OX40-OX40L pathway: a new era in atopic dermatitis management by T cell rebalancing","author":"Nakajima","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103900_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2025.103900_bb0665","article-title":"Role of TL1A in inflammatory autoimmune diseases: a comprehensive review","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103900_bb0670","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103900_bb0675","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cpdd.1040","article-title":"A randomized phase 1 evaluation of deupirfenidone, a novel deuterium-containing drug candidate for interstitial lung disease and other inflammatory and fibrotic diseases","volume":"11","author":"Chen","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.autrev.2025.103900_bb0680","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7046","article-title":"Deupirfenidone compared to placebo and pirfenidone in idiopathic pulmonary fibrosis: ELEVATE IPF phase 2b trial","volume":"211","author":"Maher","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.autrev.2025.103900_bb0690","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103900_bb0695","first-page":"41","article-title":"Management of rheumatoid arthritis patients with interstitial lung disease: safety of biological antirheumatic drugs and assessment of pulmonary fibrosis","volume":"9","author":"Mori","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103900_bb0700","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11061755","article-title":"Better safe than sorry: rheumatoid arthritis, interstitial lung disease, and medication-a narrative review","volume":"11","author":"Andronache","year":"2023","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.autrev.2025.103900_bb0705","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0710","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/keae544","article-title":"Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?","volume":"64","author":"Hofman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103900_bb0715","article-title":"Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems","volume":"9","author":"Watanabe","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0720","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003426","article-title":"Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review","volume":"9","author":"Petelytska","year":"2023","journal-title":"RMD Open"},{"issue":"159","key":"10.1016\/j.autrev.2025.103900_bb0725","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0340-2020","article-title":"Natural variability in the disease course of SSc-ILD: implications for treatment","volume":"30","author":"Vonk","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0730","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103900_bb0735","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003850","article-title":"Pretreatment mortality risk prediction model in patients with polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"10","author":"Gui","year":"2024","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.autrev.2025.103900_bb0740","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41577-024-01043-3","article-title":"Single-cell analysis in rheumatic and allergic diseases: insights for clinical practice","volume":"24","author":"Nishide","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103900_bb0745","article-title":"The burden of progressive-fibrosing interstitial lung diseases","volume":"9","author":"Cottin","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.autrev.2025.103900_bb0750","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s12325-022-02066-9","article-title":"Healthcare resource utilization and related costs in chronic fibrosing interstitial lung diseases with a progressive phenotype: a US claims database analysis","volume":"39","author":"Olson","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103900_bb0755","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00221-2021","article-title":"The burden of progressive fibrotic interstitial lung disease across the UK","volume":"58","author":"Simpson","year":"2021","journal-title":"Eur Respir J"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:53:20Z","timestamp":1763769200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":149,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1568997225001612"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103900","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103900"}}